Erorr
Erorr
Erorr

Pasbion News

Erorr

Acceleron takes back drug rights from Celgene to start pulmonary push

Acceleron's long-running collaboration with Celgene on sotatercept has taken another turn today, with an amendment of their agreement to give Acceleron the right to develop the drug for pulmonary diseases.

Read More

Ex-Glaxo CEO Witty joins Hatteras as venture partner

Sir Andrew Witty has joined Hatteras Venture Partners. The former GlaxoSmithKline CEO is taking up a venture partner position at the VC shop, setting him up to offer advice on the positioning of its portfolio companies.

Read More

Atlas neurological upstart Disarm gains $30M, AbbVie backing

Disarm Therapeutics has seen a strong $30 million series A round as it looks for a breakthrough approach in axonal degeneration.

Read More

Flagship seeks $500M for sixth fund; unveils another microbiome firm

Cambridge, MA-based venture capital group Flagship Pioneering has filed a $500 million offering with the Securities & Exchange Commission to set up a sixth investment fund.

Read More

Bruised Ultragenyx attempts swoop for in-demand Dimension

It looked like a done deal: Last month, Regenxbio penned a pact to acquire Dimension Therapeutics for the modest sum of $86 million as it looked to add two early-stage gene therapies to its pipeline.

Read More

Phase 3 antibiotic win sends Nabriva stock into overdrive

A phase 3 trial of Nabriva Therapeutics’ antibiotic lefamulin has met its primary endpoint. The drug held its own against established treatment moxifloxacin, raising hopes that Nabriva can establish it as a first-line monotherapy treatment of community-acquired bacterial pneumonia.

Read More

Blocking mTor could thwart HIV replication in the gut

HIV can hide in immune cells called CD4 T cells, creating reservoirs that allow the virus to survive and replicate. Researchers at the University of Montreal Hospital Research Centre say they’ve discovered a way to block this replication in the stomach.

Read More

Atlas-incubated Rodin sculpts out $27M for neurological work

Upstart Rodin Therapeutics has gained $27 million as it plots clinical work on a new Alzheimer’s candidate next year.

Read More

Gates invests in Immunocore to spur infectious disease R&D

The Bill & Melinda Gates Foundation is investing up to $40 million in Immunocore to spur research into the use of T cell receptor-based therapeutics to treat tuberculosis and HIV.

Read More

Mustang picks up CD20 CAR-T from Fred Hutch

Mustang Bio has picked up the rights to a CD20-directed CAR-T therapy from Fred Hutchinson Cancer Research Center. The agreement gives the Fortress Biotech offshoot a phase 1/2-ready cell therapy to advance alongside its existing clutch of CAR-Ts.

Read More

Lilly/Incyte's baricitinib musters mixed data in atopic dermatitis trial

In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective, prompting unfavorable comparisons with Sanofi and Regeneron's recently approved Dupixent.

Read More

Bavarian Nordic tanks after Bristol-Myers-partnered vaccine flunks phase 3 prostate cancer trial

Bavarian Nordic’s repeatedly delayed phase 3 cancer vaccine trial has come crashing to a halt. The data monitoring committee ended the six-year odyssey after ruling it would be futile to keep treating patients with the Bristol-Myers Squibb-partnered Prostvac.

Read More

Chutes & Ladders—Teva recruits Lundbeck chief Schultz with $52M package

Lundbeck chief Kåre Schultz will be paid a $52 million package to helm Teva, former CDC director Tom Frieden is leading a new $225 million global health initiative, Roivant Sciences tapped Eisai and Pfizer vet Allen Waxman as its general counsel, plus more hirings, firings and retirings throughout the industry.

Read More

How seaweed could help heal traumatic brain injuries

Traumatic brain injury (TBI) causes long-term irreversible damage largely because inflammation prevents the regrowth of healthy brain tissue. So Australian scientists went on the hunt for a natural compound that could halt that inflammation—and they found it in something that’s plentiful in their country: seaweed.

Read More

Sanofi, Lexicon trot out more data backing SGLT1/2 medication sotagliflozin in Type 1 diabetes

A cadre of SGLT2 medications may have beaten Sanofi and Lexicon to that fast-growing market, but they aim to carve out a place for their experimental drug sotagliflozin in Type 1 diabetes. Based on data parsed at EASD, the companies plan to file for FDA approval in early 2018.

Read More

Moderna changes up R&D model, posts cancer, CV trial updates

Moderna has once again dumped a whole load of updates as it looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.

Read More

Vanda's atopic dermatitis drug misses mark in mid-stage trial

Atopic dermatitis is being pitched as a big new market for immune-modifying drugs, but is a tough drug development prospect—as Vanda Pharmaceuticals has just found out.

Read More

Otonomy axes staff, hits brakes on R&D after phase 3 flop

Otonomy is hunkering down after a phase 3 wipeout devastated its near-term prospects. The ear disease firm is laying off one-third of its noncommercial staff and hitting pause on its remaining pipeline programs.

Read More

Seeking an edge in a fiercely fought field, Bristol-Myers pays Halozyme $105M to access I-O delivery tech

Bristol-Myers Squibb has paid Halozyme $105 million upfront to access drug delivery technology. The agreement positions Bristol-Myers to develop subcutaneous formulations of molecules against PD-1 and 10 other immuno-oncology targets.

Read More

Can the culprit for cancer spreading also boost immuno-oncology treatments?

Lymphatic vessels are tiny structures that drain fluid from the body—but they are also blamed for carrying cancer cells from the primary tumor to other locations in the body. Now a research team led by the University of Chicago has discovered that these vessels can enable immune cells to kill cancer cells.

Read More

BridgeBio Pharma gains $135M for genetic disease work

Early-stage Californian biotech BridgeBio Pharma has completed a $135 million financing round as it looks to push deeper into genetic disease R&D.

Read More

Amicus ditches skin disorder drug after late-stage failure

A drug for rare skin disease epidermolysis bullosa that Amicus Therapeutics acquired in a $847 million deal two years ago has failed a key phase 3 trial.

Read More

Bayer taps Berkeley Lights to automate drug discovery

Bayer and Berkeley Lights are embarking on a strategic project to discover antibodies and ramp up the development of cell lines. The Big Pharma will use Berkeley Lights’ Beacon platform to automate biological processes in the drug development process.

Read More

Rocket to merge with Inotek to bag Nasdaq listing, plots gene therapy trials

Rocket Pharmaceuticals has landed a Nasdaq listing through a reverse merger. The deal will see the low-profile gene therapy startup merge with floundering Inotek Pharmaceuticals before embarking on a clutch of clinical trials.

Read More

ProQR spins out CNS assets to form RNA rare disease biotech

ProQR has spun out its CNS assets to form Amylon Therapeutics. The offshoot starts life with seed funding and an RNA-based program targeting a rare genetic disease that causes strokes.

Read More

Contact Us

PASBION HEALTHCARE INC
1747 S. Douglass Road, Suite C
Anaheim, California 92806
714.231.9876

PASBION HEALTHCARE INC
Building No X111/2a. M.C Road,
Kalady-683 574,Ernakulam Dist,
Kerala, India
+91 -8606 44 88 90
info@pasbion.com

Contact Us

Erorr

PASBION HEALTHCARE INC

1747 S. Douglass Road, Suite C

Anaheim, California 92806

714.231.9876